(E)-N'-((5-(4-Chlorophenoxy)-3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene)-4-nitrobenzohydrazide (PNH), a pyrazole-hydrazide-based chemosensor, was designed for the selective detection of fluoride ions using dual-mode colorimetric and fluorometric responses. When PNH interacts with fluoride ions, it shows a clear colour shift from colourless to brilliant yellow and a turn-on fluorescence emission at 510 nm, but it is insensitive to other common anions. Its high sensitivity was confirmed by UV-visible and fluorescence titration tests, which showed a 12 nM detection limit and satisfactory linearity. The sensing study was further supported by 1H NMR titrations. Additionally, DFT investigations were used to theoretically validate the suggested binding mechanism of the F-ion interaction with the receptor. Crucially, the development of polymer-based films and paper strip devices, which allow for quick, portable, and visible detection of fluoride ions without the need for complex equipment, demonstrates the sensor's practical application.

OBJECTIVE:Neuroinflammation and oxidative stress play key roles in cognitive decline and memory impairments. This study employed a lipopolysaccharide (LPS)-induced neurotoxicity model and in silico methods, including in silico docking and dynamic simulations, to assess the therapeutic potential of Oxyphenbutazone (OPB). MATERIALS AND METHODS:Wistar rats were categorized as control, LPS-only section, LPS + OPB receiving low (35 mg/kg) and high (70 mg/kg) doses of OPB, and only OPB (70 mg/kg) doses. Behavioral assessments (Y-maze and Morris water tests) were used to assess cognitive ability. The levels of neuroinflammatory markers [Interleukin-6 (IL-6), IL-1β, and tumor necrosis factor-alpha (TNF-α)] and oxidative stress modulators [Superoxide dismutase (SOD), glutathione (GSH), catalase (CAT), and malondialdehyde (MDA)] were estimated. Additionally, transforming growth factor-beta (TGF-β), nuclear factor-kappa B (NF-κB), and inhibitor of kappa B-alpha (IκB-α) levels were evaluated. In silico analyses, such as molecular docking and dynamic simulations, were used to evaluate the stability of OPB and target molecules. RESULTS:Cognitive performance improved after OPB treatment, and the levels of proinflammatory cytokines, antioxidants, TGF-β, NF-κB, and IκB-α were restored. Additionally, in silico analyses illustrated favorable and stable interactions between OPB and the target molecules NF-κB and IκB-α. CONCLUSION:These findings suggest the therapeutic potential of OPB in mitigating neurotoxicity and the associated cognitive disabilities.

The purpose of this study was to develop a lipid polymer hybrid nanoparticle (LPNs) for the codelivery of Vinorelbine (VBL) and Rutin (RUT) for the treatment of hepatic carcinoma. The VBL loaded LPNs (VBL-LPNs), and VBL and RUT loaded LPNs (VBL-RUT-LPNs) were prepared using PLGA (polymer) and dynasan 114 (lipid) by probe sonication and high pressure homogenization method. The VBL-LPNs and VBL-RUT-LPNs exhibited a particle size (260 f 5.40 and 298 f 3.51 nm), PDI (0.312 f 0.03 and 0.286 f 0.03), ZP (-18.8 f 2.60 and-19.8 f 2.70 mV), EE (73.7 f 1.52 and 77.9 f 2.19 %) and LC (2.3 f 0.49 and 2.5 f 0.73 %), respectively. In- vitro release studies exhibited a sustained release patter for 48 h, with korsmayer peppas kinetics model. No significant changes in VBL-LPNs and VBL-RUT-LPNs was confirmed by stability studies. As compared to free VBL and VBL-LPNs, we observed increased cytotoxicity and lowered inhibitory concentration IC50 in HepG2 cells treated with VBL-RUT-LPNs, indicating the synergistic effects of VBL and RUT. The VBL-RUT-LPNs also upregulated caspase 3 and downregulated Bcl-2, indicating a successful apoptosis. When combined, VBL and RUT are delivered concurrently by VBL-RUT-LPNs, which may offer a promising treatment for hepatic carcinoma.

The study examined the use of Melissa essential oil (MEO) in kappa carrageenan (KC) based films as a form of active packaging for potential applications in food packaging. Concentrations of MEO used were 0.1 %, 0.5 %, 1 %, and 1.5 % (v/v) to observe changes in the biopolymer characteristics. The films were evaluated for their appearance, color, antioxidant properties, and mechanical characteristics, including tensile strength (TS) and elongation at break (EAB). The findings indicate that the increase in MEO concentration resulted in a considerable decrease in the TS and moisture content of the films. In addition, an increase in EAB and water vapor permeability (WVP) was observed due to the increase in MEO concentration. The results of color analysis show that higher MEO levels made the films opaque with increasing yellowness (b*). Moreover, antioxidant assays revealed that increasing the concentration of MEO significantly improved the films' scavenging activity against free radicals (DPPH) and cationic radicals (ABTS+). Additionally, characterization techniques such as FTIR, XRD, SEM, and thermal assessments (TGA, DSC and DTG) were also performed. Microstructural analysis revealed that a higher MEO concentration led to a few particles in the film structure. Overall, the results indicate a relatively consistent microstructure. The thermal analysis revealed that the increase in MEO concentration leads to a noticeable improvement in the film's thermal stability.

Objectives: This research aimed to assess the potential outcome of rosinidin on Scopolamine (SCOP)-induced memory dysfunction in a rat model. Methods: Adult Wistar rats were grouped (n = 6) as: Groups 1 (normal control) and 2 (SCOP control) received 0.5 percent SCMC (vehicle, 3 mL) orally; Groups 3 and 4 administered rosinidin (10 and 20 mg/k g) orally. Over 14 days of therapeutic intervention, Group 1 received normal saline one h after the above-mentioned oral treatments, and the remaining group of rats were given SCOP (1 mg/kg, i.p.). Rats were tested for spontaneous movement, learning, and memory capacities. The hippocampus of rats were collected and analyzed for oxidative stress markers [reduced glutathione (GSH), superoxide dismutase (SOD), catalase, and malondialdehyde (MDA)], pro-inflammatory markers [(Interleukin-1 beta (IL-1 beta), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha)], acetylcholinesterase (AChE), choline acetyltransferase activity (ChAT), brain-derived neurotrophic factor (BDNF), nuclear factor-kappa B (NF-kappa B), and nuclear factor erythroid 2-related factor 2 (Nrf2), and D] Toll-like Receptor 4 (TLR4). Results: Rosinidin significantly improved spatial learning and memory in SCOP-treated rats, as shown by reduced escape latency in the Morris water maze (MWM) test and increased SAP% in the Y-maze test (P < 0.001). Additionally, SCOP caused memory loss in animals, decreased GSH, SOD, and catalase, altered AChE and ChAT activity, increased malondialdehyde (MDA), nitrate, TNF-alpha, NF-kappa B, IL-1 beta, IL-6, and TLR4, as well as decreased IL-6, BDNF, and Nrf2 (P < 0.001). Rosinidin administration at both doses (10 and 20 mg/kg) restored the SCOP-induced behavioral deficits and biochemical markers to normal (P < 0.001). These findings indicate its potential to reverse SCOP-induced cognitive deficits. Conclusions: The findings suggest that rosinidin effectively ameliorates SCOP-induced memory deficits in rats. This improvement may be linked to restored cholinergic function, modulated oxidative stress, and suppressed neuroinflammation.

AIM:The investigation aimed to study the outcome of rosiridin in Parkinson's disease (PD) induced by rotenone (ROT) in rodents. METHODS:Rodents were randomized into IV groups and were induced with ROT followed by treatment with rosiridin. Group I-IV received saline as a vehicle, II-ROT (0.5 mg/kg S.C) for 28 consecutive days, III and IV- rosiridin 10 and 20 mg/kg orally with ROT. On completion of the experimental duration, behavioral investigations were carried out. Biochemical variables such as acetylcholinesterase (AChE), oxidative stress and antioxidants markers (Malondialdehyde-MDA, glutathione-GSH, superoxide dismutase-SOD, and catalase-CAT), anti-inflammatory (Interleukin-1 beta-IL-1β, IL-6, and tumor necrosis factor alpha-TNF-α), alteration in neurotransmitters (Serotonin-5-HT), norepinephrine, and dopamine-DA, along with metabolites such as 5-hydroxy indole acetic acid-5- HIAA),), mitochondrial complex I, II, IV, and caspase-3 activity were evaluated at the end of the experiment. Furthermore, molecular docking and dynamics were performed for target ligands. RESULTS:Rosiridin significantly restored the level of AChE, oxidative stress and antioxidants markers (MDA, GSH, SOD, and CAT), anti-inflammatory (IL-1β, IL-6, and TNF-α), alteration in neurotransmitters, mitochondrial complex I, II, IV, and caspase-3 activity. Rosiridin has a favorable negative binding affinity to AChE (-8.99 kcal/mol). The results of the molecular dynamics simulations indicate that proteins undergo a substantial change in conformational dynamics when binding to rosiridin. CONCLUSION:In this study, rosiridin may exhibit neuroprotective properties against the Parkinson's model for treating PD.

This study aimed to explore a nanogel formulation containing acemannan as a carrier for the treatment of psoriasis-like skin inflammation. Several acemannan concentrations, such as F1 (2.5 %) and F2 (5 %), were used to prepare the nanogel formulation by homogenization. The formulation was then assessed for in-vitro performance. Four groups of animals were randomly assigned to the animals: Cluster I consisted of normal saline control; Cluster II was assigned Imiquimod (IMQ) control (5 %); Cluster III was assigned IMQ + 2.5 % acemannan (F1); and Cluster IV was assigned IMQ + 5 % acemannan (F2). The effectiveness of the gel in the in vivo study was evaluated in terms of body weight, scaly skin, skin redness, inflammation, patches, moisturizing effect, pro-inflammatory cytokines, nitric oxide, and histopathological examination. The prepared nanogel possessed the desired characteristics in terms of in vitro evaluation parameters. The average particle size was around 199.6 nm, with a polydispersibility index (PDI) of 0.338 and a zeta potential of -65.9 mV. The nanogel formulation significantly (P < 0.05) regulated in vivo performance, including redness, scaly skin, inflammation, patches, moisturizing effect, pro-inflammatory cytokines, and nitric oxide. The histopathological findings suggested that acemannan was effective in rejuvenating the affected skin.

The growing use of silver (Ag) and copper (Cu) nanoparticles (NPs) for their antimicrobial properties has raised environmental health concerns due to their coexistence in aquatic ecosystems. This study assessed the combined physiological and molecular toxicity of AgNPs and CuNPs in rainbow trout (Oncorhynchus mykiss) exposed to sub-lethal concentrations of the NP mixture for 21 days. Fish were exposed to varying concentrations of co-exposure of AgNPs and CuNPs (T1 group 0.2 AgNPs + 0.2 mg/L CuNPs, T2 group 0.8 AgNPs + 0.6 mg/L CuNPs, and T3 group 1.4 AgNPs + 1.0 mg/L CuNPs). Behavioral alterations were evident, accompanied by a significant (p < 0.05) reduction in hemoglobin, red blood cell count, and hematocrit levels, while white blood cell counts increased, indicating immune activation. Serum biochemical analyses revealed metabolic disturbances linked to oxidative stress and physiological imbalance. Enzymatic activities in gills and liver showed a dynamic response, with elevated catalase (CAT) and superoxide dismutase (SOD) levels at T2 and T3 after 14 days, followed by a decline by day 21. Glutathione S-transferase (GST) activity increased in gills at T2 and T3 after 7 days and in the liver at T3 after 14 days, while lipid peroxidation (LPO) significantly increased in gills at T3 after 7 days and in the liver at T2 and T3 after 14 days. Molecular analysis confirmed upregulation of oxidative stress genes (SOD1, CAT) and inflammatory markers (HSP70, IL- 1β). Histopathological examination revealed gill damage, including lamellar fusion and hyperplasia, and liver degeneration, such as hepatocyte vacuolation and necrosis, with the most severe effects observed at T3. These findings highlight dose-dependent toxicity and oxidative damage caused by the AgNPs-CuONPs mixture, emphasizing its potential physiological and molecular impacts on aquatic organisms.

Europinidin is a novel anthocyanidin found in the petals of Plumbago europea that exhibits several physiological effects. Research was conducted to assess europinidin’s cardioprotective efficacy in a diabetic and myocardial infarction (MI) experimental model. Rat was injected through the intraperitoneal administration of 45 mg/kg of streptozotocin (STZ), while MI was induced by subcutaneously administering 85 mg/kg of isoproterenol (ISP) at 24 and 48 h prior to the sacrifice procedure. Europinidin 10 and 20 mg/day was administered orally for 4 weeks after validation of diabetes (glucose > 250 mg/dl) on the 7th day. Experimental rats were randomly allocated to control, STZ-ISP control, STZ-ISP + europinidin-10 mg, STZ-ISP + europinidin-20 mg and europinidin 20 mg perse group. Biochemicals parameters including anti-diabetic (Glucose, HbA1c, serum insulin), cardiac markers (hs-CRP, CPK-MB), dyslipidaemia (lipid analysis), anti-inflammatory (IL6, TNF-α and IL-β), oxidative stress (MDA) and antioxidant (SOD, CAT and GSH), kidney function (creatinine), liver function (AST) and pancreatic function (lipase) along with apoptosis markers (Bcl-2, caspase-3) were evaluated. In addition, histopathological indices of heart injury were investigated. In addition, molecular docking (AUTODOCK Tools 1.5.6.) and dynamics were performed. Europinidin (10 and 20 mg/day) reduced blood glucose, HbA1c, hs-CRP, and CPK-MB. It improved serum insulin, blood lipid profile and reduced inflammatory cytokines (IL-6, TNF-α, IL-β), oxidative stress and increased antioxidant enzymes (SOD, CAT and GSH). Europinidin also protected renal, hepatic functions and restored apoptosis markers (increased Bcl-2, decreased caspase-3 levels). Histopathological analysis demonstrated a reduced extent of myocardial necrosis and fibrosis. Europinidin binds in silico to proteins 1NME, 1I0E, 3I2Y and 4AQ3 with energies of -7.038, -6.682, -8.6 and − 8.761 kcal/mol, respectively. While molecular dynamics simulation studies supported the interactions of europinidin with important therapeutic target proteins. Europinidin demonstrates significant cardioprotective and anti-diabetic potential in a diabetic MI experimental model.

This research aimed to determine if europinidin-o-methylated anthocyanidin could protect rats from memory and learning impairments induced by scopolamine (SCOP). The experiment involved four groups of Wistar rats with normal control, SCOP-treated group, europinidin (10 mg/kg and 20 mg/kg p.o.) for 14-day. After that, assessments of movement, memory recall, and learning were conducted. Brain tissue was analyzed for various markers, namely choline acetyltransferase (ChAT), acetylcholine esterase (AChE), antioxidants, nitrites, antiinflammatory, and brain-derived neurotrophic factor (BDNF). SCOP significantly impaired memory and altered brain chemistry. Europinidin treatment, however, reversed these effects, improving neurobehavioral function, reducing oxidative stress and inflammation, and restoring AChE, ChAT, and BDNF levels. Docking studies further revealed europinidin's favourable interaction with ChAT, supporting its protective mechanism. Europinidin showed favorable affinity towards ChAT with docking scores of-8.77 kcal/mol. The study demonstrates europinidin effectiveness in mitigating SCOP-induced memory deficits among rats.

Memory loss or dementia is a progressive disorder, and one of its common forms is Alzheimer’s disease (AD), effecting mostly middle aged and older adults. In the present study, we developed Rivastigmine (RIV) nanoparticles using poly(lactic-co-glycolic acid) (RIV-loaded PLGA NPs) and polyvinyl alcohol (PVA). The prepared RIV-PLGA nanoparticles was evaluated for the management of Alzheimer's disease (AD). The nanoparticles were prepared by the slightly modified nano-precipitation technique. The developed formulations were evaluated for particle size, zeta potential (ZP), polydispersibility index (PDI) and surface morphology and drug content. The experimental result revealed that prepared RIV-loaded PLGA NPs (F1) was optimized having particle size (61.2 ± 4.6 nm), PDI (0.292), ZP (−11.2 ± 1.2). SEM study confirms the prepared nanoparticles depicted non-aggregated as well smooth surface particles without any fracture. This formulation (F1) was further assessed for in vivo studies on animal model. A pharmacological screening on an animal model of Alzheimer's disease revealed that RIV-loaded PLGA NPs formulations treat CNS disorders like Alzheimer's effectively. In addition to that, an in-vivo brain cholinesterase estimation study found that, animals treated with optimized formulation significantly (p < 0.01) reduced brain cholinesterase activity when compared to scopolamine-treated animals. According to the above results, it can be concluded that RIV-loaded PLGA NPs are ideal carriers for delivering the drug at a specific target site in the brain, thus may treat Alzheimer's disease efficiently and improve patient compliance.

Alzheimer's disease (AD) is a long-term neurodegenerative condition characterized by impaired cognitive functions, particularly in the domains of learning and memory. Finding promising options for AD can be successful with a medication repurposing strategy. The goal of the research was to examine the neuroprotective characteristics of barbaloin in aluminum chloride (AlCl3)-induced cognitive deficits and changes in rats through modulation of oxidative stress, cytokines, and brain-derived neurotrophic factor (BDNF) expression. Thirty male Wistar rats were subjected to AlCl3 at a dosage of 100 mg/kg via the per oral route (p.o.), which induced cognitive decline. Morris water maze (MWM) is used to assess behavioral metrics. Assays for catalase (CAT), malondialdehyde (MDA), reduced glutathione (GSH), acetylcholinesterase (AChE), choline-acetyltransferase (ChAT), interleukins-1β (IL-1β), superoxide dismutase (SOD), tumor necrosis factor-α (TNF-α), nuclear factor kappa-B (NF-κB), interleukins-6 (IL-6), BDNF, and neurotransmitter levels [dopamine (DA), acetylcholine (Ach), and γ-aminobutyric acid (GABA)] were performed. Results: The transfer latency time was notably decreased, and substantial modifications in the concentrations of GSH, MDA, CAT, SOD, AChE, ChAT and observed modulations in the formation of interleukins-6 (IL-6), TNF-α, IL-1β, BDNF, and NF-κB were also evidenced after the treatment of rats with barbaloin in comparison to AlCl3-induced control groups. Significant alterations in neurotransmitter levels (DA, Ach, and GABA) were also seen in barbaloin-treated groups in comparison to AlCl3-induced groups. The current investigation has provided evidence that the administration of barbaloin yielded notable enhancements in cognitive function in rats through the inhibition of MDA, enhancing endogenous antioxidant enzymes, reduction of cytokine levels, and enhancement of neurotransmitter contents in the brain. These effects were observed in comparison to a control group treated with AlCl3 and can be attributable to barbaloin's strong anti-inflammatory and antioxidant properties, and metal chelating properties may contribute to its neuroprotective effects. Barbaloin may also promote neuronal survival and enhance learning and memory by upregulating the expression of BDNF.

Background/Objectives: 6-Shogaol is a comparatively innovative anti-Parkinson’s remedy with antioxidant and anti-inflammatory characteristics. This investigation intended to determine the role of 6-shogaol in the Parkinson’s disease (PD) paradigm in rotenone-induced rats. Methods: Thirty male Wistar rats (10–12 weeks old; 180 ± 20 g) were divided into five groups. Animals with rotenone-induced experimental PD were subsequently treated with 6-shogaol-10 at 20 mg/kg for 28 days. After the experimental duration, behavioural investigations were performed, i.e., open field test, forced swim test, rotarod test, and catalepsy test. Biochemical assessments like AChE, GSH, CAT, SOD, MDA, nitrite, ceruloplasmin, proinflammatory markers such as IL-1β, NF-κB, TNF-α, and catecholamines markers (DA, GABA, and MAO-B) were determined. The docking procedure was conducted using the AutoDock Vina docking protocol. Furthermore, histopathology was performed. Results: Rotenone significantly increased the level of MAO-B, oxidative, nitrative, and pro-inflammatory markers. However, there was a decline in ceruloplasmin, dopamine, and endogenous antioxidants. Treatment with 6-shogaol (10 and 20 mg/kg) considerably sustained the elevation of oxidative stress and inflammatory indicators and decreased AChE activity and dopamine levels. In the histology of the brain, 6-shogaol improved the neuronal structure and reduced the degeneration of neurons. Based on the binding energy values, compound 6-shogaol demonstrates a favourable binding affinity to AChE, MAO-B, DA, and GABA with respective binding energies of −8.214, −8.133, −7.396 and −6.189 kcal/mol. Conclusions: In this study, 6-shogaol exhibited neuroprotective properties against PD, which could be employed as a prospective medication for PD.

The orexin receptor antagonist (ORA) is one of the new psychopharmacological agents used in the treatment of insomnia. There are currently no documented greener high-performance liquid chromatography-diode array detector (HPLC-DAD) methods for the analysis of ORA antagonists, lemborexant (LMB) and suvorexant (SUV) simultaneously. Therefore, in this study, a simple, sensitive, and greener HPLC-DAD method has been developed for the simultaneous quantitative analysis of LMB and SUV in bulk and laboratory-prepared mixture. The developed method was validated for numerous validation parameters and evaluated for greenness. The C-18 Waters Spherisorb CN (4.6 x 250 mm(2); 5 mu m) column was used for the chromatographic separation. The mobile phase composition was ethanol: 10 mM KH2PO4 buffer in a ratio of (60:40 v/v). The DAD detection was performed at 253 nm using a Waters DAD detector. The greenness was evaluated using the analytical Eco-Scale (AES), ChlorTox, and analytical GREEnness (AGREE) techniques. The calibration curves showed excellent linearity for LMB and SUV between the concentration range of 125-5000 ng/mL and 250-10,000 ng/mL, respectively. In addition, the proposed HPLC-DAD method was accurate, precise, robust, highly sensitive, and greener. AES, ChlorTox, and AGREE scales were predicted by the HPLC-DAD method to be 91, 1.14 g, and 0.79, respectively, showing an excellent greenness profile. The greener HPLC-DAD method was successfully used to analyze both medicines quantitatively in bulk and laboratory-prepared synthetic mixtures. The findings of this study indicated that the proposed HPLC-DAD method may be consistently applied to evaluate LMB and SUV in bulk and dosage forms.

Background:Type 2 diabetes mellitus (T2DM) is defined by a wide variety of metabolic abnormalities, persistent hyperglycemia, and a slew of other complications. Catharanthus roseus L. (apocyanaceae), remarkably notable as Vinca Rosea, appears to be the source of the active component hirsutidin, which is reported in various diseases. Objective:The study intended to appraise the antidiabetic capability of hirsutidin in a high-fat diet (HFD) and streptozotocin (STZ) induced diabetes in experimental rats. Materials and methods:An experimental rodent T2DM model was elicited by consuming an HFD regimen with STZ 50 mg/kg, i.p. dose formulated in a 0.1 M cold citrate buffer (pH 4.5). The test drug hirsutidin (10 and 20 mg/kg) and the standard drug glimeclamide (5 mg/kg) were administered daily for six weeks. The efficacy of hirsutidin was observed on several diabetes parameters. The average body weight and an array of biochemical markers were determined, including blood glucose, insulin, dyslipidemia (lipid profile), total protein (TP), liver injury [aspartate aminotransferase (AST), alanine aminotransferase (ALT)], inflammation [IL-6, IL-1β, tumor necrosis factor-α (TNF-α)], oxidative stress [malondialdehyde (MDA)] and antioxidant status [catalase (CAT), glutathione (GSH), and superoxide dismutase (SOD)]. In addition, the concentrations of leptin, adiponectin, and resistin were also assessed. Also, molecular docking studies were undertaken to investigate critical targets associated with diabetes, including TNF-α, insulin, adiponectin, and leptin. Results:Diabetes induction with HFD/STZ resulted in hyperglycemia (significantly reduced blood glucose and increased insulin level), dyslipidemia (significantly reduced TC, TG and increased HDL), total protein (significantly reduced), oxidative stress and antioxidant status (significantly reduced MDA and increased CAT, SOD and GSH levels), inflammation (significantly decreased IL-6, IL-1β, TNF-α), liver damage (significantly reduced AST, ALT), and specific hormones such as adiponectin, leptin significantly improved and resistin significantly reduced as evidenced by biochemical data in this study. Intermolecular interactions of ligands and docking score, hirsutidin proteins TNF-α (2AZ5), Insulin (4IBM), Adiponectin (6KS1), Leptin (7Z3Q) with binding energy of -6.708, -7.674, -7.2 and -7.547 Kcal/mol. Conclusion:Hirsutidin may have an evidential hypoglycemic outcome and may exhibit potent antidiabetic activity in HFD/STZ-induced T2DM in rats. Treatment with hirsutidin significantly improved glycemic control, lipid metabolism, oxidative stress, inflammation, and liver function. Additionally, it normalized dysregulated levels of adiponectin, leptin, and resistin. Molecular docking confirmed its strong binding affinity to key diabetic targets.

Background and Objectives: Rosiridin is a monoterpene with outstanding monoamine inhibitory activity that is useful to treat depressive episodes and rapid-onset dementia. The current investigation aims to evaluate the neurologically protective impact of rosiridin, which opposes aluminum chloride (AlCl3) and causes memory dysfunction in rats. Materials and Methods: Memory impairment was developed in Wistar rats by administering AlCl3 (100 mg/kg p.o.) orally for 42 days and then supplemented with rosiridin at 10 and 20 mg/kg/p.o. Upon completion of the investigation, the behavior factor was performed utilizing the Y-maze, Morris Water Maze, and open field tests. Estimating numerous biological factors, such as nitric oxide (NO), oxidative stress (malondialdehyde MDA), acetylcholinesterase (AChE), butyrylcholinesterase levels (BuChE), antioxidants (glutathione GSH, catalase CAT, and superoxide dismutases SODs) and neurotransmitter (serotonin-5HT, dopamine-DA, acetylcholine-Ach) in the brain. Furthermore, interleukin-6 (IL-6), IL-1β, tumor necrosis factor (TNF-α), brain-derived neurotrophic factor (BNDF), nuclear factor kappa B (NFᴋB), phosphatidylinositol 3-kinase (PI3K), and pAkt were assessed in the diffused brain cells. Results: The rosiridin-treated group significantly improved in terms of behavioral parameters, including in the Y-maze, Morris Water Maze, and open field tests. Further, rosiridin restored biochemical parameters, including NO, oxidative stress AChE, BuChE, antioxidants, neurotransmitters, IL-6, IL-1β, TNF-α, BNDF, NFᴋB, PI3K, and pAkt compared to AlCl3. Conclusions: The current investigation reveals that rosiridin could ameliorate the impairment of memory that AlCl3 causes in rats via improvements in behavioral and restored biochemical parameters.

The analysis aimed to prepare an in-situ implant (ISFI) formulation holding dimethyl fumarate as (a model drug) using cross-linked gellan gum by homogenization method. Cross-linking of gellan gum was done with L-cysteine to improve its gelation properties. Fourier transform infrared spectroscopy (FTIR) and (DSC) Differential scanning calorimetry were used to test the compatibility of the drug-polymer. The diverse formulations were prepared and tested using Design Expert® ver 8.0.1 software to optimize the experiment technique and employ the response surface. The tissue compatibility of the test verified the existence of non-irritants in the established formulation. All preparations contained the drug content from approximately 97.98 to 99.88%. Viscosities are ideal for injection in the optimized formulation (1,55 percent w/w in water). The optimized formula was monitored, and up to 156hours, it was found to be 95.7%. The result was that ISFI can effectively monitor and control the delivery of several powerful drug products.

Background Methamphetamine (MA) is well recognized as a psychostimulant that can cause neurotoxicity and neurodegeneration, which is associated with cognitive decline, has been confirmed experimentally.Objective The research aimed to investigate the neuroprotective properties of europinidin (Eu) in rodents affected by methamphetamine (MA)-induced cognitive impairments and hippocampal alterations. This was achieved by inhibiting lipid peroxidation and pro-inflammatory markers.Methods Rats were exposed to cognitive impairment produced by MA. The Morris water maze (MWM) is utilized to evaluate behavioral parameters. Biochemical tests were conducted on malondialdehyde (MDA), catalase (CAT), interleukins-1 beta (IL-1 beta), reduced glutathione (GSH), tumor necrosis factor-alpha (TNF-alpha), superoxide dismutase (SOD), and the expression of neurotransmitters (Norepinephrine [NE], dopamine [DA], glutamate, and gamma-aminobutyric acid [GABA]) as well as cAMP response element-binding protein (CREB), IL-6, brain-derived neurotrophic factor (BDNF), and caspase 3 proteins. An investigation was carried out using docking methodology to ascertain whether Eu interacts with relevant molecular targets.Results Significant decline in the transfer latency and there were significant changes in the amount of SOD, GSH, CAT, and MDA and alterations in levels of IL-6, IL-1 beta, CREB, TNF-alpha, BDNF, and Caspase 3 proteins expression. considerably restored level of neurotransmitters (NE, DA, Glutamate, and GABA) were observed in the Eu-treated rats compared to the MA-induced rats. Eu had a favorable affinity towards BDNF with docking scores of -9.486 kcal/mol.Conclusion The experiment found that administering Eu to rats improved cognitive abilities by changing antioxidant enzymes, reducing cytokines, and modifying neurotransmitter levels, compared to rats in the control group treated with MA.

Introduction Fustin, a photogenic flavanol found in the plant Rhus verniciflua Stokes, has been involved in multiple disease ailments and has a beneficial pharmacological effect and a history of use in traditional medicine. The present research aimed to study the impact of fustin on scopolamine (SCOP)-induced memory impairment and neurodegeneration by modulating neuroinflammation and neurotransmitters in rats.Methods A total of 30 healthy Wistar rats were allocated into five groups (n=6). Group I- served as control and received saline solution (1mL/kg i.p.), group -II- fustin (100 mg/kg, orally), group -III -SCOP (1 mg/kg, i.p.), and group -IV and V were given fustin (50 and 100 mg/kg/p.o.) with SCOP (1 mg/kg, i.p.) for 14-days. After 14 days, 2 hours after SCOP injection, the Y-maze and Morris water maze (MWM) tests were performed. After behavioral tests rats were subsequently euthanized, and brain supernatants were used to estimate choline-acetyltransferase (ChAT), acetylcholinesterase (AChE), antioxidant [superoxide dismutase (SOD), catalase (CAT), and glutathione (GSH)], and total protein, oxidative stress markers [nitrate and malondialdehyde (MDA)], pro-inflammatory markers [tumor necrosis factor (TNF-alpha), and Interleukins-1 beta (IL-1 beta) and IL-6]. Also, neurotransmitters such as serotonin (5-HT), dopamine (DA), Upsilon-amino butyric acid (GABA), acetylcholine (Ach), and noradrenaline (NA) contents were performed.Results Fustin exhibited substantial behavioral improvement in the Y-maze measures spontaneous alterations percentage (SA%) and decreased latency time following the acquisition and prolonged time spent in the probe trial in the MWM test. Moreover, fustin inhibits enhanced neuroinflammatory cytokines and oxidative stress markers and improves the neurotransmitters.Conclusion The findings of this study suggest that fustin inhibits SCOP impact on cognitive abilities in rats. The present investigation demonstrates that fustin, a potent phytochemical, effectively mitigated the behavioral and physiological changes induced by SCOP in rats. This was primarily achieved by modulating the levels of inflammatory response and neurotransmitters.

Cancer is a generic term for a group of disorders defined by uncontrolled cell growth and the potential to invade or spread to other parts of the body. Gene and epigenetic alterations disrupt normal cellular control, leading to abnormal cell proliferation, resistance to cell death, blood vessel development, and metastasis (spread to other organs). One of the several routes that play an important role in the development and progression of cancer is the phosphoinositide 3-kinase (PI3K) signaling pathway. Moreover, the gene PIK3CG encodes the catalytic subunit gamma (p110γ) of phosphoinositide 3-kinase (PI3Kγ), a member of the PI3K family. Therefore, in this study, PIK3CG was targeted to inhibit cancer by identifying a novel inhibitor through computational methods. The study screened 1015 chemical fragments against PIK3CG using machine learning-based binding estimation and docking to select the potential compounds. Later, the analogues were generated from the selected hits, and 414 analogues were selected, which were further screened, and as most potential candidates, three compounds were obtained: (a) 84,332, 190,213, and 885,387. The protein–ligand complex’s stability and flexibility were then investigated by dynamic modeling. The 100 ns simulation revealed that 885,387 exhibited the steadiest deviation and constant creation of hydrogen bonds. Compared to the other compounds, 885,387 demonstrated a superior binding free energy (ΔG = −18.80 kcal/mol) with the protein when the MM/GBSA technique was used. The study determined that 885,387 showed significant therapeutic potential and justifies further experimental investigation as a possible inhibitor of the PIK3CG target implicated in cancer.